ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RVX Resverlogix Corp

0.06
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Resverlogix Corp TSX:RVX Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.06 0.06 0.065 0.06 0.06 0.06 27,687 19:42:04

Resverlogix Announces Appointment of New Chief Scientific Officer

15/08/2022 11:00pm

GlobeNewswire Inc.


Resverlogix (TSX:RVX)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Resverlogix Charts.

Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO, effective today.

“Dr. Kulikowski has a contributed tremendously since joining Resverlogix in 2005 and we are delighted to appoint her CSO,” said Donald McCaffrey, President and CEO of Resverlogix, adding “We would like to sincerely thank Dr. Wong for his innumerable contributions since co-founding Resverlogix.” Dr. Wong stated “Having reached a milestone age last month, the time has come for me to transition out of this role. Dr. Kulikowski is an absolutely outstanding scientist and an excellent choice for CSO.”

About Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.

The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us: Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/

For further information please contact:

Investor RelationsEmail: ir@resverlogix.comPhone: 403-254-9252www.resverlogix.com

1 Year Resverlogix Chart

1 Year Resverlogix Chart

1 Month Resverlogix Chart

1 Month Resverlogix Chart

Your Recent History

Delayed Upgrade Clock